Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
JBM (Healthcare) Ltd. ( (HK:2161) ) has issued an announcement.
JBM (Healthcare) Ltd. has entered into a 2025 License Agreement with Europharm, a subsidiary of Jacobson Pharma Corporation Limited, to use a portion of a factory for three years starting from January 2025. This agreement, involving a monthly license fee of HK$218,000, is classified as a connected transaction under Hong Kong’s Listing Rules, requiring reporting and announcement but exempt from circular and independent shareholders’ approval due to its financial scale.
More about JBM (Healthcare) Ltd.
YTD Price Performance: -0.53%
Average Trading Volume: 2,072,054
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$1.55B
For a thorough assessment of 2161 stock, go to TipRanks’ Stock Analysis page.